InDex Pharmaceuticals today announced that the first patent concerning the diagnostic
test DiBiCol has been granted in Japan.
With DiBiCol, the new and unique PCR-based test, inflammatory bowel diseases can be
diagnosed quickly and safely. Primarily, it is used to differentiate between ulcerative
colitis and Chron’s disease, but in addition it can exclude the less severe condition
irritable bowel syndrome (IBS).
“We are very satisfied with this approval, following up on the approval in the US last
year. We have high hopes that the DiBiCol test will become a new golden standard in
IBD/IBS diagnostics and it is of great importance that our intellectual rights in this field
are fully recognized. DiBiCol is launched on the Swedish market this year and we expect
the first reimbursement approval any day now”, says CEO Svante Rasmuson.